Clinical Trial Update: Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma [NA]

View source ↗

Summary

This NOT_YET_RECRUITING clinical trial is evaluating a three-drug combination of irinotecan liposome, capecitabine, and lenvatinib in biliary tract cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma

Drugs mentioned

• LENVIMA (lenvatinib)
• Onivyde (irinotecan hydrochloride liposome injection)
• Xeloda (capecitabine)

Snippet

Sponsor: Yunpeng Liu | Conditions: Biliary Tract Carcinoma | NA | Status: NOT_YET_RECRUITING